This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI, treated with an oral anticoagulation (OAC) and clopidogrel. Here, CYP2C19 is linked to atrial fibrillation.